With 2.01 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.79 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $129.27 whereas the lowest price it dropped to was $121.7. The 52-week range on BNTX shows that it touched its highest point at $131.49 and its lowest point at $76.53 during that stretch. It currently has a 1-year price target of $135.78. Beta for the stock currently stands at 0.17.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BNTX was up-trending over the past week, with a rise of 12.70%, but this was up by 6.77% over a month. Three-month performance surged to 4.39% while six-month performance rose 57.60%. The stock gained 13.63% in the past year, while it has gained 11.35% so far this year. A look at the trailing 12-month EPS for BNTX yields -2.15 with Next year EPS estimates of -3.40. For the next quarter, that number is 0.45. This implies an EPS growth rate of -181.02% for this year and -5.99% for next year.
Float and Shares Shorts:
At present, 239.74 million BNTX shares are outstanding with a float of 239.44 million shares on hand for trading. On 2024-12-13, short shares totaled 2.33 million, which was 97.0 higher than short shares on 1731628800. In addition to Dr. Ugur Sahin M.D. as the firm’s Co-Founder, CEO & Chair of the Management Board, Dr. Ozlem Tureci M.D. serves as its Co-Founder, Chief Medical Officer & Member of Management Board.
Institutional Ownership:
Through their ownership of 0.20645 of BNTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BNTX reported revenue of $1244800000.0 and operating income of $10500000.0. The EBITDA in the recently reported quarter was $211100000.0 and diluted EPS was $0.81.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BNTX since 13 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 2 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BNTX analysts setting a high price target of 163.725 and a low target of 115.253, the average target price over the next 12 months is 131.40115. Based on these targets, BNTX could surge 29.04% to reach the target high and fall by -9.16% to reach the target low. Reaching the average price target will result in a growth of 3.56% from current levels.
Analysts have provided yearly estimates in a range of -$1.43186 being high and -$4.38769 being low. For BNTX, this leads to a yearly average estimate of -$3.10655.
